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Differential Survival of Hamster-to-Rat Liver and Cardiac Xenografts 
Under FK 506 Immunosuppression 
LA Valdivia. J.J. Fung, AJ. Demetns. and T.E. Starzl 
THE ~aj~r bame~ in clinical transplantation has been the hmltatlon ot donor organs. I Xenotransplantation 
has been considered an alternative source of organs, 
however strong immunolOgiC barriers are thought to make 
this option impractical. 
The immunosuppressant FK 506 has been shown to be 
several hundred times more potent than cyclosporine 
(CyA)2.) and it is capable of suppressing antibody produc· 
tion. 4 These qualities would justify a tnal of this drug in 
experimental organ xenografts. Indeed. Nakajima et als 
failed to prolong hamster cardiac xenogralts in rat recipi-
-. ents treated with FK 506. However. It has been demon-
strated that untreated livers survive longer than the hearts 
in the same xenograft combination.6 •7 Thus. in this study 
we investigated the effect of FK S06 in the difficult ham· 
ster-to-rat liver and cardiac xenotransplant model and 
compared the results with those of Cy A. 
MATERIALS AND METHODS 
Male LVG hamsters 4100 to 150 g) and male Lewis rats 1240 to 280 
g) served as donors and reCipients. respecuvely. OrthotopIC liver 
transplantation tOL TI was perfonned accordlOg to the cuI! tech-
niqueK~ Donor cholecystectomy was carned out at the time of 
grafting and the preparation lacked anastomosIS of the hepauc 
artery. HeterotopIc heart transplantation tHll was perfonned by 
a microsurl!lcal technIque as described by Ono and Lindsey! 
Treatment groups were given either FK 506 or eyA by 1M 
IOjectlon for 14 days tshon-tenn Immunosuppression I. or FK·S06 
I or 2 m!!/kgld for the first posttransplant month followed by dose 
reduction to O.S mgtkg every other day up to day 100 (Iong-tenn 
immunosuppressIon). Graft SUrvival and liver funclIon were mono 
ilored. Anuhamster cytotoxIc antibody levels were detennlOed by 
complement-dependent cytotoxicity assay (COC) as preVIously 
described.' BiOPSIes. postmortem specimens. or those taken at 
~acrifice were fixed in 10% formalin and stained with hematoxylin 
and eosin. 
RESULTS 
Xenograft survival is shown in Table I. Liver xenograft 
recipients given low-dose FK 506 (0.25 mgt kg) rejected 
their grafts in 7 days, as controls. Short-term treatment 
With a dose of 0.5 mgtkgld FK 506 increased hepatic 
xenograft survival to a mean of 47 days. On the other hand. 
a high dose of Cy A resulted in moderate prolongation to 13 
days. with five out of seven rats rejecting while sull under 
treatment. Long-term Immunosuppression with 1 mg/kgld 
FK 506 for 30 days. followed by 0.5 mgtkg every other day 
up to day 100. kept five out of eight recipients alive for 
more than 80 days after grafting. The same long-term 
protocol with 2 mg/kgld FK 506 prolonged liver xenograft 
survival for more than 100 days in 8 out of 12 rats. At the 
time of writing five recipients are still alive. the longest 
survivor alive at 200 days after transplantation and 100 
days after FK 506 withdrawal. Unlike liver xenografts 
neither FK 506 nor CyA was able to produce clinically 
significant survival of HTx. Figure 1 shows the results of 
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Table 1. U.,.. and Cardiac Xenogl'lltt SurvIVIIl Under FK 508 or CyA Immunosupprwalon 
No. Organ 
Grouo TreatrnenI T,.,..,.. 
1 None BOLT 
2 FK 506: 0.25 mgtkgtd (short·tennl SOLT 
3 FK 506: 0.5 mgtkgtd (shott·tennl SOLT 
4 eVA: 30 mgtkgtd (short-term) 70lT 
5 FK 506: 1 mgtkgtd (Iong-tenn) 80LT 
6 FK 506: 2 mgtkgtd (lang-term) 120lT 
7 None 6HT 
8 FK 506: M~R mgtkgtd 6HT 
9 FK 506: 1.0 mgtkgtd 6HT 
10 FK 506: 1.5 mgtkgtd SHT 
11 FK 506: 2.0 mgtkgtd SHT 
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Fig 1. BiochemlC8l profiles in liver xenograft reapients under 
short-term FK 506 or CyA immunosuppressIOn. 
liver functions in xenograft recipients under short-term 
immunosuppression. FK S06 kept glutarmc oxaloacetic 
transaminase tGOT). alkaline phosphatase. total bilirubin. 
and total protem at normal or near normal levels when 
compared with those of controls or CyA-treated animals. 
The best mdicator of rejection seems to be alkaline phos-
phatase. showing increasing values after FK 506 adminis-
tration was stopped on day 14. 
The antibody response to liver xenografts on short-term 
immunosuppression is shown in Fig 2. After an initial rise 
in cytotoxic antibody titers that was similar to that of 
Cy A-treated recipients. FK S06-treated animals showed 
suppression of antibody formation. After FK S06 with-
drawal on day 14. anubody titers started to rise again by 
the third week. Untreated liver xenograft recipients 
showed a rapid elevation in antibody titers from I: 1 on day 
o to around I :8.192 at rejection time. Long-term treatment 
with either I or 2 mgtkg FK 506 (Fig 3) completely 
suppressed the initial humoral response by the third post-
transplant week. This antibody suppression was long-
lasting since rats surviving for more than 100 days do not 
have any cytotoxIc antibody titer despite no longer receiv-
ing FK 506. There was no suppression of anubody re-
sponse to cardiac xenografts by either low- or high-dose 
FK 506. 
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Fig 2. Antihamster cytotoxic antibody titers In liver xenograft 
reaptents under shOrt·term FK 506 or CyA immunosuppreSSIOn. 
After 30 minutes Incubation of the recipient'S serum and comple-
ment With hamster lymph node cells (5 x 1 06!mL), the percentage 
of cells stained with trypan blue was calculated. A score of 200/0 
cell death was constdered positive. Guinea pig serum diluted 1 :10 
served as the source of complement. 
Histologic examination of liver xenografts in untreated 
controls at rejection time showed prominent portal and 
central venulitis with marked portal edema and moderate 
infiltrate of histiocytes. plasma cells. and lymphocytes (in 
order of predominance I. CyA treatment did not change 
these findings. One liver xenograft who received low-dose 
FK 506 for 2 weeks and was killed on the last day of 
treatment presented focal mild portal infiltrate with blastic 
cells. Essentially. the liver was normal except for focal 
rejection infiltrate. Open liver biopSies (day 24) were 
performed in two xenograft recipients under long-term 
immunosuppression with FK 506 (I and 2 mgJkg). Except 
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Fig 3. Antthamster cytOtoXic antibody liters In liver xenograft 
r8Ql)ler1ta under tong-term FK 506 ~K
FK 506 THERAPY ON LIVER. HEART XENOGRAFTS 
for mild bile duct proliferation there was no acute cellular 
rejection. The same features were observed in one rat that 
died from aspiration pneumonia 50 days after transplanta-
tion. and in another recipient that died on day 109 of a 
cardiac condition due to widespread calcification oi the left 
atrium. One liver xenograft reCipient underwent liver bi-
opsy on day 150. This animal had no antibody titers in the 
serum. however. histologic findings revealed that a brisk 
cellular acute rejection is ongoing, with biliary duct dam-
age but no lobular necrosIs. This particular recipient is still 
alive at 200 days after transplantation and it is doing 
clinically well. 
Untreated cardiac xenografts presented characteristic 
humoral-mediated rejection and these findings could not 
be changed by FK 506. 
DISCUSSION 
-The first attempts to prevent hepatic xenograft relectlon in 
the hamster-to-rat model using CyA combined with sple-
nectomv. ~ or the addition of total lymphOid irradiation 
<ILl) to the former therapy. 10 resulted in only a moderate 
prolongation but not in long-term recipient survival. The 
difficulty in this xenograft model is the fact that antlbody-
complement mechanisms are primarily responsible for 
rejection of extrahepatic xenografts."· 12 while liver xe-
nografts undergo a combination of both humoral and 
cellular rejection. ~ In this context. our results with FK 506 
alone producing long-term survival of liver xenografts. 
even with clinically applicable dosing, are remarkable. 
Notably. we have demonstrated that only the liver is 
favored by this immunosuppressant because the heart 
succumbs to the early vigorous humoral rejection. An 
interesting development would be to investigate if a liver 
xenograft could protect the heart or other organs from 
rejection. as It has been demonstrated with liver allografts 
protectlng kidneys irom the same donors In presensltlzed 
humans. 13 
There are several important observations to be made in 
this study. Naive Lewis rats do have preformed anubodies 
against hamster lymphocytes. though in very low titers. 
Because of this they would fail to Induce hyperacute 
rejection. In a matter of days. however. cytotoxic antibod-
ies are induced in extremely high titers. Although both FK 
506 and Cy A suppressed moderately this initial humoral 
response. antibody titers were still above the level that is 
usually found at the time of cardiac xenograft rejection in 
this model. Thus. not only hepatic allografts 14 but hepatic 
xenografts are unusually resistant to humoral injury. On 
the other hand. we have found that CyA-treated animals 
presented more cellular infiltrate than untreated xe-
nografts. while in the recipients receiving FK 506 there 
3271 
were only minimal portal fntlammatory cells. Thus. the 
difference between both drugs might be in their ability to 
suppress cellular-mediated rejection. 
A striking finding in this study is that under FK 506 
treatment the humoral and cellular responses from the 
.xenograft recipient waned by the end of the third week. 
provided that the treatment was continued. No animal 
presented cellular rejection or cytotoxic antibody titers 
while under long-term immunosuppression. no matter that 
the FK 506 dose was reduced. Only 50 days after FK 506 
administration was stopped. cellular but not humoral re-
jection is under way. This lack of antibodies would ex-
plain. in part. how a xenograft recipient does not develop 
immune complex-related diseases. such as serum sickness 
and arthritis.7 
In conclusion. this is the first report of a successful liver 
.xenograft in a model that is immunologically difficult to 
overcome. FK 506 is largely more etfective than eyA in 
this xenograft system but ItS etfect favors only the liver and 
not the hean xenotransplants. A successful clinical liver 
\enotransplantation with FK 506 immunosuppression 
looks highly possible. especially in a combination in which 
preformed antibodies are present in low titers and there is 
no hyperacute rejection. but in the end rejection is mainly 
humoral-mediated. in other words. the baboon-to-human 
system. 
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